Mavorixafor trihydrochloride

Overview

Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC 50 value of 13 nM against CXCR4 125 I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC 50 of 1 and 9 nM, respectively.Mavorixafor trihydrochloride can be used for the study of WHIM syndrome.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Viral Infection | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CXCR | Products > Signaling Pathways > HIV

Product Information

• Catalog No.: HY-50101A
• CAS No.: 2309699-17-8
• Molecular Formula: C21H30Cl3N5
• Molecular Weight: 458.86
• Purity: 99.75%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.62 mg/mL (5.71 mM); Clear solution
• Availability: In-stock

Source

Original product source